Safety and efficacy of a recombinant DNA Plasmodium falciparum sporozoite vaccine.

No abstract is available for this paper.

• Publication year

  1987

• Venue

  The Lancet

• Publication date

  1987-06-06

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1016/S0140-6736(87)90540-XPMID 2884410
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Plasmodium falciparum: sporozoite boosting of immunity due to a T-cell epitope on a sporozoite vaccine.

  1987cited by this paper
• Construction of synthetic immunogen: use of new T-helper epitope on malaria circumsporozoite protein.

  1987cited by this paper
• Immunogenicity in infants of a vaccine composed of Haemophilus influenzae type b capsular polysaccharide mixed with DPT or conjugated to diphtheria toxoid.

  1987cited by this paper
• Efficacy of murine malaria sporozoite vaccines: implications for human vaccine development.

  1987cited by this paper
• Plasmodium falciparum: immunogenicity of circumsporozoite protein constructs produced in Escherichia coli.

  1987cited by this paper
• Sporozoite Malaria Vaccines

  1986cited by this paper
• Malaria transmitted to humans by mosquitoes infected from cultured Plasmodium falciparum.

  1986cited by this paper
• Immunity to malaria and naturally acquired antibodies to the circumsporozoite protein of Plasmodium falciparum.

  1986cited by this paper
• Genetic control of the immune response in mice to a Plasmodium falciparum sporozoite vaccine. Widespread nonresponsiveness to single malaria T epitope in highly repetitive vaccine

  1986cited by this paper
• Isotype concentrations of human antibodies to group A meningococcal polysaccharide.

  1986cited by this paper
• Immunogenicity of synthetic peptides from circumsporozoite protein of Plasmodium falciparum.

  1985cited by this paper
• Expression of Plasmodium falciparum circumsporozoite proteins in Escherichia coli for potential use in a human malaria vaccine.

  1985cited by this paper
• Inhibition of entry of Plasmodium falciparum and P. vivax sporozoites into cultured cells; an in vitro assay of protective antibodies.

  1984cited by this paper
• Structure of the gene encoding the immunodominant surface antigen on the sporozoite of the human malaria parasite Plasmodium falciparum.

  1984cited by this paper
• Gonococcal pilus vaccine. Studies of antigenicity and inhibition of attachment.

  1981cited by this paper
• Monovalent fragments (Fab) of monoclonal antibodies to a sporozoite surface antigen (Pb44) protect mice against malarial infection

  1980cited by this paper
• Use of attenuated sporozoites in the immunization of human volunteers against falciparum malaria.

  1979cited by this paper
• Studies on the transfer of protective immunity with lymphoid cells from mice immune to malaria sporozoites.

  1978cited by this paper
• Immunity to sporozoite-induced malaria infeciton in mice. I. The effect of immunization of T and B cell-deficient mice.

  1977cited by this paper
• Immunization of man against falciparum and vivax malaria by use of attenuated sporozoites.

  1975cited by this paper
• Protective immunity produced by the injection of x-irradiated sporozoites of Plasmodium berghei. V. In vitro effects of immune serum on sporozoites.

  1969cited by this paper
• Protective immunity produced by the injection of x-irradiated sporozoites of Plasmodium berghei. IV. Dose response, specificity and humoral immunity.

  1969cited by this paper
• Protective Immunity produced by the Injection of X-irradiated Sporozoites of Plasmodium berghei

  1967cited by this paper

• Virus-like particles: a versatile and effective vaccine platform

  2025cites this paper
• Current Developments in Malaria Vaccination: A Concise Review on Implementation, Challenges, and Future Directions

  2025cites this paper
• Evaluation of in-vivo antimalarial potential of Xanthium strumarium, Bergenia ciliata, and Nicandra physalodes fractions against chloroquine-resistant Plasmodium berghei

  2025cites this paper
• Malaria vaccines: the 60-year journey of hope and final success—lessons learned and future prospects

  2023cites this paper
• Sporozoite immunization: innovative translational science to support the fight against malaria

  2023cites this paper
• Controlled Human Malaria Infection Studies in Africa—Past, Present, and Future

  2022cites this paper
• Controlled Human Infection Models To Accelerate Vaccine Development

  2022cites this paper
• Malaria Vaccines

  2022cites this paper
• First-in-human assessment of safety and immunogenicity of low and high doses of Plasmodium falciparum malaria protein 013 (FMP013) administered intramuscularly with ALFQ adjuvant in healthy malaria-naïve adults.

  2022cites this paper
• Liposomes for malaria management: the evolution from 1980 to 2020

  2021cites this paper
• The challenges of a circumsporozoite protein-based malaria vaccine

  2021cites this paper
• Insights from modelling malaria vaccines for policy decisions: the focus on RTS,S

  2021cites this paper
• Identification of a neutralizing epitope within minor repeat region of Plasmodium falciparum CS protein

  2021cites this paper
• Emerging therapeutic modalities against malaria

  2021cites this paper
• Malaria Vaccines: Prospects and Problems

  2020cites this paper
• Application of Radiation Technology: A Novel Vaccine Approach to Induce Protective Immunity against Malaria Infection

  2020cites this paper
• Future use-cases of vaccines in malaria control and elimination

  2020influential citation
• Liposome Formulations as Adjuvants for Vaccines.

  2020cites this paper
• Biological Membranes and Malaria-Parasites

  2019cites this paper
• The world's first malaria vaccine – promising clinical results

  2019cites this paper
• Antibodies against Plasmodium falciparum malaria at the molecular level

  2019cites this paper
• Immunogenicity of synthetic peptide constructs based on PvMSP9E795-A808, a linear B-cell epitope of the P. vivax Merozoite Surface Protein-9.

  2019cites this paper
• RTS,S/AS01 vaccine (Mosquirix™): an overview

  2019cites this paper
• Whole parasite vaccines for the asexual blood stages of Plasmodium

  2019cites this paper
• Role of Complement in Immunity Against Malaria

  2018cites this paper
• Complement Activation in Malaria Immunity and Pathogenesis

  2018cites this paper
• Downstream processing of malaria vaccine candidates and modeling of chromatography

  2018cites this paper
• Plasmodium vivax Controlled Human Malaria Infection – Progress and Prospects

  2017cites this paper
• PIPS one Safety and Immunogenicity of a Recombinant Plasmodium falciparum AMA 1 Malaria Vaccine Adjuvanted with Alhydrogel TM , Montanide ISA 720 or AS 02

  2017cites this paper
• Development of whole sporozoite malaria vaccines

  2017cites this paper
• Liposomes containing monophosphoryl lipid A and QS-21 serve as an effective adjuvant for soluble circumsporozoite protein malaria vaccine FMP013.

  2017cites this paper
• Controlled Human Malaria Infection: Applications, Advances, and Challenges

  2017cites this paper
• Targeting the Parasite to Suppress Malaria Transmission.

  2017cites this paper
• Rhesus macaque and mouse models for down-selecting circumsporozoite protein based malaria vaccines differ significantly in immunogenicity and functional outcomes

  2017cites this paper
• Drug resistance in malaria.

  2017cites this paper
• Liposomal adjuvants for human vaccines

  2016cites this paper
• Infectivity of Plasmodium falciparum in Malaria-Naive Individuals Is Related to Knob Expression and Cytoadherence of the Parasite

  2016cites this paper
• Mechanisms of invasion from sporozoite and merozoíto of Plasmodium

  2016cites this paper
• Mosquito bite immunization with radiation-attenuated Plasmodium falciparum sporozoites: safety, tolerability, protective efficacy and humoral immunogenicity

  2016cites this paper
• Antimalarial drug resistance: An overview

  2016cites this paper
• From reverse to structural vaccinology : profiling of CyRPA as new Plasmodium falciparum malaria vaccine candidate antigen

  2015cites this paper
• Progress with Plasmodium falciparum sporozoite (PfSPZ)-based malaria vaccines

  2015cites this paper
• The march toward malaria vaccines.

  2015cites this paper
• The March Toward Malaria Vaccines.

  2015cites this paper
• Development of cultured Plasmodium falciparum blood-stage malaria cell banks for early phase in vivo clinical trial assessment of anti-malaria drugs and vaccines

  2015cites this paper
• Controlled human malaria infection.

  2014cites this paper
• Evaluation of chimeric virus-like particles, capsomeres and bacterial minicells as vaccine delivery platforms

  2014cites this paper
• Malaria vaccine development: over 40 years of trials and tribulations

  2014cites this paper
• Malaria vaccines: reflections on 40 years of basic research and translation applications

  2014cites this paper
• Hepatitis B core–based virus–like particles to present heterologous epitopes

  2013cites this paper
• Phase 2 a trial of 0 , 1 , and 3 month and 0 , 7 , and 28 day immunization schedules of malaria vaccine RTS , S / AS 02 in malaria-näıve adults at the Walter

  2013cites this paper
• Serological responses to a soluble recombinant chimeric Plasmodium vivax circumsporozoite protein in VK210 and VK247 population

  2013cites this paper
• Successful Human Infection with P. falciparum Using Three Aseptic Anopheles stephensi Mosquitoes: A New Model for Controlled Human Malaria Infection

  2013cites this paper
• Controlled Human Malaria Infections by Intradermal Injection of Cryopreserved Plasmodium falciparum Sporozoites

  2013cites this paper
• Experimental infection and protection against Plasmodium falciparum malaria in humans

  2013influential citation
• Optimising Controlled Human Malaria Infection Studies Using Cryopreserved P. falciparum Parasites Administered by Needle and Syringe

  2013cites this paper
• Immune Responses to Defined Plasmodium falciparum Antigens and Disease Susceptibility in Two Subpopulations of Northern India

  2013cites this paper
• Where Are We in the Quest for Vaccines for Malaria?

  2012cites this paper
• Malaria vaccine development using synthetic peptides as a technical platform.

  2012cites this paper
• The Current Status of Malaria Vaccines

  2012cites this paper
• Roles of the Amino Terminal Region and Repeat Region of the Plasmodium berghei Circumsporozoite Protein in Parasite Infectivity

  2012cites this paper
• Pre-erythrocytic malaria vaccines: identifying the targets

  2012cites this paper
• Immunogenicity of a virosomally-formulated Plasmodium falciparum GLURP-MSP3 chimeric protein-based malaria vaccine candidate in comparison to adjuvanted formulations

  2011influential citation
• Development of the RTS,S/AS Vaccine Candidate from Concept to Phase III

  2011cites this paper
• Our impasse in developing a malaria vaccine

  2011cites this paper
• CHAPTER 96 – Malaria

  2011cites this paper
• Vaccines against malaria

  2011cites this paper
• The case for a subunit vaccine against malaria.

  2011cites this paper
• A whole parasite vaccine to control the blood stages of Plasmodium: the case for lateral thinking.

  2011cites this paper
• Protective Immunity Induced with the RTS,S/AS Vaccine Is Associated with IL-2 and TNF-α Producing Effector and Central Memory CD4+ T Cells

  2011cites this paper
• One con for glob Vaccines against malaria

  2011cites this paper
• From the circumsporozoite protein to the RTS,S/AS candidate vaccine

  2010cites this paper
• Experimental human challenge infections can accelerate clinical malaria vaccine development

  2010cites this paper
• Le candidat vaccin antipaludique RTS,S/AS est entr en essais cliniques de phase III

  2010cites this paper
• Malaria vaccine design: immunological considerations.

  2010cites this paper
• Malaria vaccine: why is it taking so long?

  2010cites this paper
• The RTS,S malaria vaccine.

  2010cites this paper
• [The malaria vaccine candidate RTS,S/AS is in phase III clinical trials].

  2010cites this paper
• Malaria vaccines - The long synthetic peptide approach: Technical and conceptual advancements.

  2010cites this paper
• Parasite vaccines - recent progress and problems associated with their development.

  2010cites this paper
• Immunology and Immunopathology of Human Parasitic Infections

  2010cites this paper
• Development in malarial vaccine: A review.

  2010cites this paper
• Functional immunoassays using an in-vitro malaria liver-stage infection model: where do we go from here?

  2009cites this paper
• The hope but challenge for developing a vaccine that might control malaria

  2009cites this paper
• Randomized, double-blind, phase 2a trial of falciparum malaria vaccines RTS,S/AS01B and RTS,S/AS02A in malaria-naive adults: safety, efficacy, and immunologic associates of protection.

  2009cites this paper
• Development of the RTS,S/AS malaria candidate vaccine.

  2009cites this paper
• Malaria vaccines - how and when to proceed?

  2009cites this paper
• The development of the RTS,S malaria vaccine candidate: challenges and lessons

  2009cites this paper
• The N-terminal domain of Plasmodium falciparum circumsporozoite protein represents a target of protective immunity.

  2009cites this paper
• Genetic complexity and population diversity of Plasmodium falciparum in the Peruvian Amazon

  2009cites this paper
• Immunological mechanisms underlying protection mediated by RTS,S: a review of the available data

  2009cites this paper
• Plasmodium falciparum circumsporozoite protein: epidemiological variations among field isolates prevalent in India

  2009cites this paper
• Safety and Immunogenicity of a Recombinant Plasmodium falciparum AMA1 Malaria Vaccine Adjuvanted with Alhydrogel™, Montanide ISA 720 or AS02

  2008cites this paper
• Evaluation of adenoviral vectors

  2008cites this paper
• Phase 2a trial of 0, 1, and 3 month and 0, 7, and 28 day immunization schedules of malaria vaccine RTS,S/AS02 in malaria-naïve adults at the Walter Reed Army Institute of Research.

  2008cites this paper
• Phase I Trial of an Alhydrogel Adjuvanted Hepatitis B Core Virus-Like Particle Containing Epitopes of Plasmodium falciparum Circumsporozoite Protein

  2008cites this paper
• Malaria vaccine: a current perspective.

  2008cites this paper
• Malaria: The end of the beginning

  2008cites this paper
• [Advances in the development of a malaria vaccine].

  2008cites this paper
• Aspectos de transdução de sinal em Plasmodium.

  2008cites this paper